Article

Age-related heterogeneity in immune responses to SARS-CoV-2 vaccine BNT162b2

2021-02-05

Abstract excerpt

Two dose mRNA vaccination provides excellent protection against SARS-CoV-2. However, there are few data on vaccine efficacy in elderly individuals above the age of 80 1 . Additionally, new variants of concern (VOC) with reduced sensitivity to neutralising antibodies have raised fears for vulnerable groups. Here we assessed humoral and cellular immune responses following vaccination with mRNA vaccine BNT162b2 2 i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b772fee5-dd45-59e2-8f37-13998c71e4c3
DOI: 10.1101/2021.02.03.21251054

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Age-related heterogeneity in immune responses to SARS-CoV-2 vaccine BNT162b2DOI 10.1101/2021.02.03.21251054Read

Age-related heterogeneity in immune responses to SARS-CoV-2 following BNT162b2 vaccinationSemantic proximity Read

Competent immune responses to SARS-CoV-2 variants in older adults following mRNA vaccinationSemantic proximity Read

BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian VariantSemantic proximity Read

SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodiesSemantic proximity Read

Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in aged peopleSemantic proximity Read

STUDY PROTOCOL A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): A trial conducted within the VACCELERATE networkSemantic proximity Read

SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodiesSemantic proximity Read

Immunogenicity and Reactogenicity of a First Booster with NT162b2or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1)Semantic proximity Read

Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipientsSemantic proximity Read

Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adultsSemantic proximity Read

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.Semantic proximity Read

Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Elderly People Over 85 Years of Age in GreeceSemantic proximity Read